Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia

Abstract

There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant <i>Enterobacteriaceae</i> infections. At our center, ceftazidime-avibactam treatment of carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteremia was associated with higher rates of clinical success (<i>P</i> = 0.006) and survival (<i>P</i> = 0.01) than other regimens. Across treatment groups, there were no differences in underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced <i>K. pneumoniae</i> carbapenemase). Aminoglycoside- and colistin-containing regimens were associated with increased rates of nephrotoxicity (<i>P</i> = 0.002).